TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) and Nevro (NYSE:NVRO – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.
Risk & Volatility
TriSalus Life Sciences has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, Nevro has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and price targets for TriSalus Life Sciences and Nevro, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TriSalus Life Sciences | 0 | 0 | 3 | 0 | 3.00 |
| Nevro | 3 | 11 | 0 | 0 | 1.79 |
Valuation & Earnings
This table compares TriSalus Life Sciences and Nevro’s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TriSalus Life Sciences | $21.98 million | 7.10 | -$59.04 million | N/A | N/A |
| Nevro | $426.10 million | 0.48 | -$92.21 million | ($2.29) | -2.44 |
TriSalus Life Sciences has higher earnings, but lower revenue than Nevro.
Institutional & Insider Ownership
2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 95.5% of Nevro shares are owned by institutional investors. 76.2% of TriSalus Life Sciences shares are owned by company insiders. Comparatively, 3.2% of Nevro shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares TriSalus Life Sciences and Nevro’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TriSalus Life Sciences | N/A | N/A | -221.65% |
| Nevro | -19.17% | -27.48% | -13.40% |
Summary
TriSalus Life Sciences beats Nevro on 8 of the 12 factors compared between the two stocks.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
About Nevro
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
